Trial · NCT03508453
IC14 for Treatment of Amyotrophic Lateral Sclerosis
NCT03508453, Phase 2, Withdrawn, Implicit Bioscience
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IC14 for Treatment of Amyotrophic Lateral Sclerosis. Trials, record NCT03508453. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03508453
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IC14 for Treatment of Amyotrophic Lateral Sclerosis
- NCT number
- NCT03508453
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Implicit Bioscience
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Interventions
- IC14, Placebo
- First posted
- 2018-04-25
- Last updated
- 2026-05-05
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neurofilament (biomarker) | 12 weeks | Treatment-related change in concentration of neurofilament (picograms per milliliter) |
| Primary | Urinary p75 neurotrophin receptor (biomarker) | 12 weeks | Treatment-related change in concentration of urinary p75 neurotrophin receptor (nanograms per milligram creatinine) |
| Primary | Monocyte CD14 receptor occupancy | 12 weeks | Treatment-related change in percent monocyte receptor occupancy |
| Secondary | Functional status | 12 weeks | Treatment-related change in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale \[0 (worst) to 48 (best)\] |
| Secondary | Respiratory function | 12 weeks | Treatment-related change in percent normal Forced Vital Capacity \[0% (worst) to 100%(best)\] |
| Secondary | Muscle function | 12 weeks | Treatment-related change in percent normal Sniff Nasal Pressure \[0% (worst) to 100% (best)\] |
| Secondary | Quality of life measured by ALSSQOL | 12 weeks | Treatment-related change in Amyotrophic Lateral Sclerosis Specific Quality of Life - Revised questionnaire \[0 (worst) to 460 (best)\] |
| Secondary | Cognitive and behavioural assessment | 12 weeks | Treatment-related change in Edinburgh Cognitive and Behavioural Assessment Score \[0(worst) to 136 (best)\] |
| Secondary | Maximum plasma concentration (Cmax) | 12 weeks | Maximum serum IC14 concentration (micrograms per milliliter) |
| Secondary | Area under the curve | 12 weeks | Area under the curve for serum IC14 (microgram x hr/mL) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03508453
GET https://conductscience.org/api/trials/v1/NCT03508453/registered